Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Beam Therapeutics Inc. (BEAM : NSDQ)

• Company Description    Beam Therapeutics Inc. is a biotechnology company. It engages in developing precision genetic medicines through base editing. Beam Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 483

• Price / Volume Information    Yesterday's Closing Price: $25.42 Daily Weekly Monthly 20 Day Moving Average: 2,456,871 shares Shares Outstanding: 101.16 (millions) Market Capitalization: $2,571.54 (millions) Beta: 2.25 52 Week High: $35.25 52 Week Low: $13.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.96% 10.33% 12 Week 18.01% 12.07% Year To Date 2.50% -9.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 238 Main Street - CAMBRIDGE,MA 02142 USA ph: 857-327-8775 fax: - investors@beamtx.com https://beamtx.com

• General Corporate Information    Officers John Evans - Chief Executive Officer and Director Sravan Emany - Chief Financial Officer Bethany Cavanagh - Senior Vice President; Finance and Treasurer Graham Cooper - Director Chirfi Guindo - Director Peer Information Beam Therapeutics Inc. (CORR.) Beam Therapeutics Inc. (RSPI) Beam Therapeutics Inc. (CGXP) Beam Therapeutics Inc. (BGEN) Beam Therapeutics Inc. (GTBP) Beam Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07373V105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 101.16 Most Recent Split Date: (:1) Beta: 2.25 Market Capitalization: $2,571.54 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.02 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 11.27% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.46 Price/Cash Flow: - Price / Sales: 42.67 EPS Growth vs. Year Ago Period: 9.91% vs. Previous Quarter: 19.35% Sales Growth vs. Year Ago Period: -28.08% vs. Previous Quarter: 13.33% ROE 09/30/25 - - 06/30/25 - -43.15 03/31/25 - -44.24 ROA 09/30/25 - - 06/30/25 - -31.06 03/31/25 - -30.97 Current Ratio 09/30/25 - - 06/30/25 - 6.75 03/31/25 - 8.81 Quick Ratio 09/30/25 - - 06/30/25 - 6.75 03/31/25 - 8.81 Operating Margin 09/30/25 - - 06/30/25 - -661.31 03/31/25 - -609.24 Net Margin 09/30/25 - - 06/30/25 - -661.31 03/31/25 - -609.24 Pre-Tax Margin 09/30/25 - - 06/30/25 - -661.31 03/31/25 - -609.18 Book Value 09/30/25 - - 06/30/25 - 10.35 03/31/25 - 11.17 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©